Antidepressant treatment of posttraumatic stress disorder

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 7, 2000, Pages 40-43

  Pearlstein, Teri ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BUTLER HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; MONOAMINE OXIDASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; HUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS; DOUBLE-BLIND METHOD; HUMANS; LITHIUM; MONOAMINE OXIDASE INHIBITORS; PLACEBOS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME; TRIAZINES; VALPROIC ACID;

EID: 0034014730     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Davis LL, Suris A, Lambert MT, et al. Post-traumatic stress disorder and serotonin: new directions for research and treatment. J Psychiatry Neurosci 1997;22:318-326
2. Connor KM, Davidson JR. The role of serotonin in posttraumatic stress disorder: neurobiology and pharmacotherapy. CNS Spectrums 1998;3(suppl 2):43-51
3. Charney DS, Davidson JR, Friedman M, et al. A consensus meeting on effective research practice in PTSD. CNS Spectrums 1998;3(suppl 2):7-10
4. Southwick SM, Yehuda R, Giller EL, et al. Use of tricyclics and monoamine oxidase inhibitors in the treatment of PTSD: a quantitative review. In: Murburg MM, ed. Catecholamine Function in Post-Traumatic Stress Disorder: Emerging Concepts. Washington, DC: American Psychiatric Press; 1994:293-305
5. Reist C, Kauffmann CD, Haier RJ, et al. A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry 1989;146: 513-516
6. Davidson J, Kudler H, Smith R, et al. Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 1990;47: 259-266
7. Shestatzky M, Greenberg D, Lerer B. A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatry Res 1988;24:149-155
8. Frank JB, Kosten TR, Gilier EL, et al. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry 1988;145:1289-1291
9. Kosten TR, Frank JB, Dan E, et al. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 1991;179: 366-370
10. Baker DG, Diamond BI, Gillette G, et al. A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology (Berl) 1995;122: 386-389
11. Katz RJ, Lott MH, Arbus P, et al. Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety 1994-95;1:169-174
12. Neal LA, Shapland W, Fox C. An open trial of moclobemide in the treatment of post-traumatic stress disorder. Int Clin Psychopharmacol 1997;12: 231-237
13. Davidson J, Roth S, Newman E. Fluoxetine in post-traumatic stress disorder. J Trauma Stress 1991;4:419-423
14. McDougle CJ, Southwick SM, Charney DS, et al. An open trial of fluoxetine in the treatment of posttraumatic stress disorder [letter]. J Clin Psychopharmacol 1991;11:325-327
15. Shay J. Fluoxetine reduces explosiveness and elevates mood of Vietnam combat vets with PTSD. J Trauma Stress 1992;5:97-101
16. Nagy LM, Morgan CA, Southwick SM, et al. Open prospective trial of fluoxetine for posttraumatic stress disorder. J Clin Psychopharmacol 1993;13: 107-113
17. van der Kolk BA, Dreyfuss D, Michaels M, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994;55:517-522
18. Connor KM. Sutherland SM, Tupler LA, et al. Fluoxetine in post-traumatic stress disorder: randomised, double-blind study. Br J Psychiatry 1999;175: 17-22
19. Connor KM, Davidson JR, Tupler LA, et al. Pharmacotherapy for civilians with posttraumatic stress disorder: differential response patterns of fluoxetine and placebo. Presented at the 38th annual meeting of the New Clinical Drug Evaluation Unit; June 10-13, 1998; Boca Raton, Fla
20. Kline NA, Dow BM, Brown SA, et al. Sertraline efficacy in depressed combat veterans with post-traumatic stress disorder [letter]. Am J Psychiatry 1994;151:621
21. Rothbaum BO, Ninan PT, Thomas L. Sertraline in the treatment of rape victims with posttraumatic stress disorder. J Trauma Stress 1996;9: 865-871
22. Brady KT, Sonne SC, Roberts JM. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J Clin Psychiatry 1995; 56:502-505
23. Davidson J, van der Kolk B, Brady K, et al. Double-blind comparison of sertraline and placebo in patients with post-traumatic stress disorder. Presented at the 10th annual meeting of the European College of Neuropharmacology; September 15, 1997; Vienna, Austria
24. Brady K, Pearlstein T, Asnis GM, et al. Double-blind placebo-controlled study of the efficacy and safety of sertraline treatment of posttraumatic stress disorder. JAMA. In press
25. Rothbaum BO, Sikes CR, Farfel GM. Double-blind multicenter trials of sertraline and placebo in patients with post-traumatic stress disorder. Presented at the 14th annual meeting of the International Society for Traumatic Studies; November 21, 1998; Washington, DC
26. De Boer M, Op den Velde W, Falger PJ, et al. Fluvoxamine treatment for chronic PTSD: a pilot study. Psychother Psychosom 1992;57:158-163
27. Marmar CR, Schoenfeld F, Weiss DS, et al. Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J Clin Psychiatry 1996;57(suppl 8):66-70
28. Davidson JR, Weisler RH, Malik M, et al. Fluvoxamine in civilians with posttraumatic stress disorder [letter]. J Clin Psychopharmacol 1998;18: 93-95
29. Escalona R, Canive J, Calais L. Fluvoxamine treatment in veterans with combat related post-traumatic stress disorder. Presented at the 39th annual meeting of the New Clinical Drug Evaluation Unit: June 1-4, 1999; Boca Raton, Fla
30. Tucker PM, Smith KL, Marx B, et al. Fluvoxamine in PTSD: improvement in physiological reactivity to trauma cues. Presented at the 39th annual meeting of the New Clinical Drug Evaluation Unit; June 1-4, 1999; Boca Raton, Fla
31. Marshall RD, Schneier FR, Fallon BA, et al. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J Clin Psychopharmacol 1998;18:10-18
32. Davidson JR, Weisler RH, Malik ML, et al. Treatment of posttraumatic stress disorder with nefazodone. Int Clin Psychopharmacol 1998;13: 111-113
33. Hertzberg MA, Feldman ME, Beckham JC, et al. Open trial of nefazodone for combat-related posttraumatic stress disorder. J Clin Psychiatry 1998; 59:460-464
34. Mellman TA, David D, Barza L. Nefazodone treatment and dream reports in chronic PTSD. Depress Anxiety 1999;9:146-148
35. Davis LL, Nugent AL, Murray J, et al. Nefazodone treatment for chronic posttraumatic stress disorder: an open trial. J Clin Psychopharmacol. In press
36. Tucker PM, Smith KL, Jones D, et al. Nefazodone in PTSD: effects on symptoms and physiological reactivity. Presented at the 38th annual meeting of the New Clinical Drug Evaluation Unit; June 10-13, 1998; Boca Raton, Fla
37. Zisook S, Chentsova-Dutton Y, Ellenor G, et al. Nefazodone in patients with treatment-refractory PTSD. In: New Research Program and Abstracts of the 151st Annual Meeting of the American Psychiatric Association; June 3, 1998; Toronto, Ontario, Canada. Abstract NR599:229
38. Hidalgo R, Hertzberg MA, Mellman T, et al. Nefazodone in post-traumatic stress disorder: results from six open-label trials. Int Clin Psychopharmacol 1999;14:61-68
39. Hertzberg MA, Feldman ME, Beckham JC, et al. Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacol 1996;16:294-298
40. Chen CJ. The obsessive quality and clomipramine treatment in PTSD [letter]. Am J Psychiatry 1991;148:1087-1088
41. Hamner MB, Frueh BC. Response to venlafaxine in a previously antidepressant treatment-resistant combat veteran with post-traumatic stress disorder. Int Clin Psychopharmacol 1998;13:233-234
42. Connor KM, Davidson JR, Weisler RH, et al. A pilot study of mirtazapine in post-traumatic stress disorder. Int Clin Psychopharmacol 1999;14:29-31
43. Herbst MD, Sokolski KN, Soratorio M. Mirtazapine treatment of PTSD. In: New Research Program and Abstracts of the 152nd Annual Meeting of the American Psychiatric Association; May 20, 1999; Washington, DC. Abstract NR689:263
44. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttrauniatic stress disorder. Biol Psychiatry 1999;45:1226-1229
45. Friedman MJ, Southwick SM. Towards pharmacotherapy for posttraumatic stress disorder. In: Friedman MJ, Charney DS, Deutch AY, eds. Neurobiological and Clinical Consequences of Stress: From Normal Adaptation to PTSD. Philadelphia, Pa: Lippincott-Raven; 1995:465-481
46. Ford N. The use of anticonvulsants in posttraumatic stress disorder: case study and overview. J Trauma Stress 1996;9:857-863
47. Clark RD, Canive JM, Calais LA, et al. Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress 1999;12:395-401
48. Goldberg JF, Whiteside JE, Cloitre M, et al. Divalproex in PTSD resulting from sexual abuse. In: New Research Program and Abstracts of the 152nd Annual Meeting of the American Psychiatric Association; May 18, 1999; Washington, DC. Abstract NR368:166
49. Petty F, Kram M, Davis LL, et al. Valproate treatment of post-traumatic stress disorder. Presented at the 39th annual meeting of the New Clinical Drug Evaluation Unit; June 1-4, 1999; Boca Raton, Fla
50. Macleod AD. Vigabatrin and posttraumatic stress disorder [letter]. J Clin Psychopharmacol 1996;16:190-191
51. Berlant J. Open-label topiramate treatment of post traumatic stress disorder. Presented at the 39th annual meeting of the New Clinical Drug Evaluation Unit; June 1-4, 1999; Boca Raton, Fla
52. Yehuda R. Managing anger and aggression in patients with posttraumatic stress disorder. J Clin Psychiatry 1999;60(suppl 15):33-37
53. Friedman MJ. Current and future drug treatment for posttraumatic stress disorder patients. Psychiatr Ann 1998;28:461-468
54. Friedman MJ. What might the psychobiology of posttraumatic stress disorder teach us about future approaches to pharmacotherapy? J Clin Psychiatry 2000;61(suppl 7):44-51